SynthesisEuropean journal of clinical pharmacology2014

Bevacizumab increases the risk of gastrointestinal perforation in cancer patients: a meta-analysis with a focus on different subgroups.

Wei-Xiang Qi et al.PubMed ↗Publisher ↗

No numbers read from the abstract.